CRTC2 and PROM1 expression in non-small cell lung cancer: analysis by Western blot and immunohistochemistry
- PMID: 25256670
- DOI: 10.1007/s13277-014-2011-0
CRTC2 and PROM1 expression in non-small cell lung cancer: analysis by Western blot and immunohistochemistry
Abstract
Accumulating evidence supports that genetic factors are another risk factors for lung cancer. Previously, we used whole exome sequencing with sanger sequencing to search for genetic-related mutations in one of four individuals from a pedigree with lung cancer history. Then, we used PCR-RFLP and direct-sequence in the sample size of 318 individuals with lung cancer (cases) and 272 controls. Recently, we detected two new genes including CRTC2 (CREB regulated transcription coactivator 2) and PROM1(human prominin-1,CD133). We investigated the CRTC2 mutation and PROM1 mutation of surgically resected NSCLC tissues (n=200). The presence or absence of CRTC2 and PROM1 mutation was analyzed by direct sequencing. The expression of CRTC2 and PROM1 was studied by western blot and immunohistochemical analysis of the lung cancer tissues which had the mutation of the two genes(cases), the samples without mutations(controls) and the normal lung tissue(controls). CRTC2 and PROM1 mutations in 5 NSCLC tissues and 3 NSCLC tissues out of the samples were identified. The positive results were closely correlated with clinicopathological features, such as male gender, adenocarcinoma, smoker status, and older age (≥55). We found that the CRTC2 and PROM1 expression were significantly higher in tissues of NSCLS with mutations than that without mutations and the normal lung tissue. The results imply that the high expression of CRTC2 and PROM1 may play an important role in the development and hereditary of NSCLC.
Similar articles
-
Identification and validation of PROM1 and CRTC2 mutations in lung cancer patients.Mol Cancer. 2014 Jan 31;13:19. doi: 10.1186/1476-4598-13-19. Mol Cancer. 2014. PMID: 24484648 Free PMC article.
-
The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.Mol Med Rep. 2013 Nov;8(5):1511-8. doi: 10.3892/mmr.2013.1667. Epub 2013 Sep 4. Mol Med Rep. 2013. PMID: 24008862
-
High CD133 expression in the nucleus and cytoplasm predicts poor prognosis in non-small cell lung cancer.Dis Markers. 2015;2015:986095. doi: 10.1155/2015/986095. Epub 2015 Jan 18. Dis Markers. 2015. PMID: 25691807 Free PMC article.
-
Overexpression of PROM1 (CD133) confers poor prognosis in non-small cell lung cancer.Int J Clin Exp Pathol. 2015 Jun 1;8(6):6589-95. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26261540 Free PMC article.
-
PROM1-mediated cell signal transduction in cancer stem cells and hepatocytes.BMB Rep. 2023 Feb;56(2):65-70. doi: 10.5483/BMBRep.2022-0203. BMB Rep. 2023. PMID: 36617467 Free PMC article. Review.
Cited by
-
CRTC2 promotes non-small cell lung cancer A549 migration and invasion in vitro.Thorac Cancer. 2018 Jan;9(1):136-141. doi: 10.1111/1759-7714.12550. Epub 2017 Nov 3. Thorac Cancer. 2018. PMID: 29105369 Free PMC article.
-
PROM1 and PROM2 expression differentially modulates clinical prognosis of cancer: a multiomics analysis.Cancer Gene Ther. 2020 Apr;27(3-4):147-167. doi: 10.1038/s41417-019-0109-7. Epub 2019 Jun 5. Cancer Gene Ther. 2020. PMID: 31164716 Free PMC article.
-
Pine needle oil induces G2/M arrest of HepG2 cells by activating the ATM pathway.Exp Ther Med. 2018 Feb;15(2):1975-1981. doi: 10.3892/etm.2017.5648. Epub 2017 Dec 15. Exp Ther Med. 2018. PMID: 29434792 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials